Amsterdam-based NorthSea Therapeutics (NST), a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics, announced that it has raised $80M (approx €70.84M) in its Series C round of funding.
Rob de Ree, NST’s CEO, says, “We are delighted to close this Series C financing, further building our strong investor syndicate with new premium funds, and with the continued support of existing investors. The fundraise will support us in taking the next steps across our clinical development pipeline, enabling NST to grow into a multi-asset company in clinical and late-clinical stage.”